20 articles
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Scientists develop potent ฮฑ5ฮฒ1 integrin inhibitor for inhalation therapy, offering new approach for severe asthma patients.
New biomarker in joint tissue correlates with inflammation severity and may explain why some patients don't respond to corticosteroids.
Advanced photon-counting CT technology reveals arterial inflammation in giant cell arteritis with superior clarity.
A 12-week study shows an app combining exercise, education, and gamification cut disease activity scores by 30% in spinal arthritis patients.
A 2025 meta-analysis of 11 RCTs finds Tฮฑ1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
Two-year study shows aggressive treatment of axial spondyloarthritis reduces arterial plaque buildup by 73% when low disease activity is achieved.
New research identifies Lp-PLA2 enzyme as therapeutic target for deadly lung disease affecting millions of workers worldwide.
Icotrokinra, a breakthrough oral peptide targeting IL-23, demonstrates significant skin clearance in psoriasis with sustained benefits through 52 weeks.
Ixekizumab demonstrated remarkable efficacy in treating children with juvenile arthritis, offering hope for better outcomes.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
Researchers repurpose mRNA-lipid nanoparticle technology to prevent and treat allergic asthma in mice, achieving ~100-fold reduction in airway eosinophils.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Senescent T cells fuel psoriasis, eczema, and rosacea through toxic secretions. New therapies may finally break the cycle.
New research reveals how IL-35 therapy prevents neutrophil trap formation, offering hope for cigarette smoke-worsened asthma.
A new in vitro study shows Thymosin ฮฑ1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
Breakthrough therapy targeting B cells demonstrates significant improvement in lupus symptoms with sustained benefits over one year.
Swedish study finds JAK inhibitors raise keratinocyte cancer risk by 39% compared to TNF inhibitors in RA patients.
